These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 22024226

  • 21. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K.
    Int J Clin Oncol; 2011 Jun; 16(3):210-20. PubMed ID: 21152943
    [Abstract] [Full Text] [Related]

  • 22. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN.
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
    [Abstract] [Full Text] [Related]

  • 23. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
    Nanba S, Ikeda F, Baba N, Takaguchi K, Senoh T, Nagano T, Seki H, Takeuchi Y, Moritou Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Iwasaki Y, Yamamoto K.
    J Clin Pathol; 2016 Mar; 69(3):226-33. PubMed ID: 26290259
    [Abstract] [Full Text] [Related]

  • 24. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [Abstract] [Full Text] [Related]

  • 25. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
    Lee SH, Jin YJ, Shin JY, Lee JW.
    Medicine (Baltimore); 2017 Jan; 96(1):e5321. PubMed ID: 28072684
    [Abstract] [Full Text] [Related]

  • 26. Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
    Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K.
    Intervirology; 2012 Jan; 55(4):306-10. PubMed ID: 21865660
    [Abstract] [Full Text] [Related]

  • 27. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M.
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [Abstract] [Full Text] [Related]

  • 28. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
    Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT.
    Clin Transplant; 2004 Apr; 18(2):166-73. PubMed ID: 15016131
    [Abstract] [Full Text] [Related]

  • 29. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.
    Chen YC, Teng W, Hsieh YC, Chen WT, Jeng WJ, Huang CH, Lin CC, Chen YC, Lin SM, Lin CY, Sheen IS.
    J Formos Med Assoc; 2019 Aug; 118(8):1239-1246. PubMed ID: 30581103
    [Abstract] [Full Text] [Related]

  • 30. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC, Kabiling C, Chen CL, Lin YH, Liu YW, Wang CC, Hu TH, Chiu KW.
    Transplantation; 2014 Apr 27; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [Abstract] [Full Text] [Related]

  • 31. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis.
    Xu J, Li J, Chen J, Liu ZJ.
    Adv Clin Exp Med; 2015 Apr 27; 24(2):331-40. PubMed ID: 25931368
    [Abstract] [Full Text] [Related]

  • 32. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Shiina S, Koike K.
    J Hepatol; 2019 Jan 27; 70(1):78-86. PubMed ID: 30336183
    [Abstract] [Full Text] [Related]

  • 33. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection.
    Saudi Med J; 2003 Jul 27; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [Abstract] [Full Text] [Related]

  • 34. Higher efficacy of antiviral therapy after major hepatectomy in patients with hepatitis B virus-related hepatocellular carcinoma of less than 3 cm.
    Zhang ZY, Zhou ZQ, Zhou GW.
    Eur J Gastroenterol Hepatol; 2014 Oct 27; 26(10):1116-24. PubMed ID: 25003747
    [Abstract] [Full Text] [Related]

  • 35. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.
    Chen PH, Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Chao Y, Lin HC, Wu JC.
    Ann Hepatol; 2013 Oct 27; 12(2):263-73. PubMed ID: 23396738
    [Abstract] [Full Text] [Related]

  • 36. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC.
    Clin Interv Aging; 2016 Oct 27; 11():1035-41. PubMed ID: 27536084
    [Abstract] [Full Text] [Related]

  • 37. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ.
    J Gastroenterol Hepatol; 2011 Sep 27; 26(9):1380-8. PubMed ID: 21884247
    [Abstract] [Full Text] [Related]

  • 38. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Sep 27; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 39. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J.
    Transplant Proc; 2010 Nov 27; 42(9):3647-51. PubMed ID: 21094833
    [Abstract] [Full Text] [Related]

  • 40. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
    Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P.
    J Hepatol; 2010 May 27; 52(5):652-7. PubMed ID: 20346533
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.